(MNTA)—RDY, Biocon not close to FDA approval for either 20mg or 40mg Copaxone, apparently. Following are excerpts from these companies’ most recent earnings calls (h/t @chiragontwtr). (Italicized comments enclosed in brackets are mine.)
Based on the observations in #msg-112804827 and #msg-112812696, it’s hardly surprising that such companies as RDY and Biocon are struggling to meet the FDA’s high threshold for sameness to branded Copaxone.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.